Changing the future of Oncology.

Leadership Team

Edward Albini, M.B.A

Chief Financial Officer

Edward Albini has served as our Chief Financial Officer since January 2013. During 2012, Mr. Albini served as a consulting Chief Financial Officer for Carbylan Biosurgery, a company focused on the development and commercialization of advanced biomaterial-based joint therapies. From 2011 to 2016, Mr. Albini also served as Chief Financial Officer and Secretary for Itero Holdings, LLC, a successor entity to Itero Biopharmaceuticals, Inc., a company focused on the development and commercialization of protein therapeutics, at which Mr. Albini served as Chief Financial Officer and Senior Vice President from 2009 to 2011. Previously, Mr. Albini served as Chief Financial Officer of Novacea, Inc. and Lynx Therapeutics, Inc., both biopharmaceutical companies. Mr. Albini received a B.S.C. in Accounting from Santa Clara University and an M.B.A. from the Walter A. Haas School of Business at the University of California, Berkeley. Mr. Albini is also a certified public accountant (inactive status) in California.

Shabbir Anik, Ph.D.

Chief Technical Operations Officer

Shabbir T. Anik, Ph.D., has served as our Chief Technical Operations Officer since March 2016. From August 2011 to December 2015, Dr. Anik served as Senior Vice President of Technical Operations at Onyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing medicines for the treatment of cancer. Previously, Dr. Anik served as President and Chief Executive Officer of Althea Technologies Inc., President of Global Pharmaceutical Development Services and Chief Scientific Officer for Patheon Inc. and in various leadership positions at Neurex Corporation and Syntex Inc. Dr. Anik received a B.S. in Pharmacy from the University of Bombay, a Ph.D. in Pharmaceutical Sciences from the University of Wisconsin, Madison and an M.B.A. from Santa Clara University.

Annie Chang, M.B.A.

Head of Investor Relations

Annie Chang has over 15 years of experience in strategic and advisory roles within the biotechnology, technology, and finance industries. She was previous at Solebury Trout as a Vice President of Investor Relations and led the investor relations and communications programs for small- and mid-cap companies in the biotechnology space. She has worked in the technology industry within corporate development and M&A functions, in asset management at a hedge fund, and in investment banking at Morgan Stanley and J.P. Morgan. Ms. Chang has a B.S. in Finance from New York University and an MBA from INSEAD.

Jane Chung, RPh

Chief Commercial Officer 

Jane Chung, RPh has over 20 years of pharmaceutical and biotechnology experience building and leading commercial teams.  Ms. Chung joins Sutro from AstraZeneca where she most recently served as President and General Manager of AstraZeneca Canada since 2019; and Vice President and Head of U.S. Immuno-Oncology franchise from 2017 to 2019; and Senior Commercial Business Director from 2015 to 2017.  Previously, Ms. Chung served as Oncology Region Sales Director and Hematology Director at Onyx Pharmaceuticals from 2013 to 2015 and held diverse roles in Commercial Operations, Marketing and Sales at Genentech from 2003 to 2013.  Ms. Chung received her B.A. from Columbia University, New York, and B.S. in Pharmacy from St. John’s University, New York.

Linda Fitzpatrick

Chief People and Communications Officer 

Linda Fitzpatrick has served as our Chief People and Communications Officer since August 2018. From January 2008 to August 2018, Ms. Fitzpatrick served as our VP of Human Resources and Communications in the capacity of Senior Advisor. In addition to her strategic consulting practice, she co-founded Parallax Venture Partners, an early stage health care venture fund in April 2002. From October 1992 to March 2002, Ms. Fitzpatrick served as Vice President of Human Resources, Corporate Communications and Operations for Gilead Sciences, Inc. and from February 1985 to September 1992 she served as Director of Investor Relations and Director of Compensation, Benefits and Systems for Genentech, Inc., in addition to heading the human resources and corporate communications strategy for a variety of publicly held biotechnology companies. Ms. Fitzpatrick also serves on a variety of non-profit boards, including board chair roles, in the science, education and community development arenas. Ms. Fitzpatrick received a B.A. in Psychology and Sociology from San Francisco State University.

Trevor Hallam, Ph.D.

President of Research and Chief Scientific Officer

Trevor J. Hallam, Ph.D., has served as our Chief Scientific Officer since December 2010. Prior to joining us, Dr. Hallam was Executive Vice President of Research & Development at Palatin Technologies, Inc., and held several senior management positions in various pharmaceutical companies, including AstraZeneca PLC, SmithKline & French Laboratories, Ltd., Glaxo Group Research Ltd., Roche Research and Rhone-Poulenc Rorer. Dr. Hallam received a BSc (Hons) in Biochemistry from the University of Leeds and a Ph.D. in Biochemistry from Kings College, University of London. He then conducted post-doctoral training at the Physiological Laboratory, University of Cambridge.

Arturo Molina, M.D., M.S., FACP

Chief Medical Officer

Arturo Molina, M.D., M.S., FACP, has served as our Chief Medical Officer since February 2016. From February 2013 to February 2016, Dr. Molina served as Vice President of Oncology Scientific Innovation at Johnson & Johnson’s California Innovation Center, an organization focused on building early stage collaborations with emerging companies. Previously, Dr. Molina served as Chief Medical Officer and Vice President of Clinical Development for Johnson and Johnson’s Ortho Biotech Oncology Research and Development, a unit of Cougar Biotechnology, Inc., Chief Medical Officer of Cougar Biotechnology, Inc., Senior Director and Interim Head of Oncology/Hematology in the Department of Medical Research and Clinical Development at Biogen Idec, Inc., and Senior Director of Medical Affairs at IDEC Pharmaceuticals Corporation. Since 2006, Dr. Molina has served as a National Advisory Committee Member for the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. From 1991 to 2002, Dr. Molina was a faculty staff physician in the Department of Hematology/Bone Marrow Transplantation and Department of Medical Oncology/Therapeutics Research at City of Hope Comprehensive Cancer Center and Adjunct Professor from 2004 to 2007. Dr. Molina was also on the Board of Directors of the City of Hope Medical Group. Dr. Molina received a B.S. in Zoology and B.A. in Psychology from the University of Texas at Austin and an M.S. in Physiology and M.D. from Stanford University School of Medicine. He is board certified in internal medicine and medical oncology, has an active California medical license and is a staff physician (volunteer) in the Oncology Clinic at the Veterans Affairs Palo Alto Health Care System. Since January 2019, Dr. Molina has been an Adjunct Clinical Associate Professor (volunteer) in the Department of Medicine, Division of Oncology, Stanford University School of Medicine.

William J. Newell 

Chief Executive Officer

William J. Newell has served as our Chief Executive Officer and a member of our Board of Directors since January 2009. Previously, he served as the President of Aerovance, Inc., a biotechnology company focused on respiratory diseases, from 2006 to 2007. Mr. Newell has also served as the Chief Business Officer and Senior Vice President at QLT Inc., in several senior management positions at Axys Pharmaceuticals, Inc., and has experience as a corporate lawyer. He currently serves on the boards of directors of  Biotechnology Innovation Organization’s Health Section and Emerging Company Section and the California Life Sciences Association, where he also serves as a member of the executive committee. Mr. Newell received an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan Law School. We believe that Mr. Newell is qualified to serve on our Board of Directors because of his experience with various biotechnology companies, including working with and serving in various executive positions in life sciences companies.

David Pauling, J.D., M.A.

General Counsel

Mr. Pauling joined Sutro in 2011 and has since held positions of increasing responsibility, including Intellectual Property Counsel, Associate General and Senior Intellectual Property Counsel, and most recently Executive Director of Legal Affairs. Prior to joining Sutro, Mr. Pauling practiced law at Jones Day and at Penne & Edmonds, LLP. Mr. Pauling received his J.D. from Santa Clara University School of Law (magna cum laude), and an M.A. in Molecular Biology and a B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz.

Brunilda Shtylla, M.B.A

VP Business Development

Ms. Shtylla worked as an independent consultant since 2012, which included consulting for Genentech since 2013. Prior to this, she held numerous positions at Lifescan, a Johnson & Johnson company, including Associate Director of Partnerships and Product Director, U.S. Brand Marketing. Previously, Ms. Shtylla held roles in Business Development, Technology Transfer, Sales & Operations Planning, Investment Banking and Finance. She received her B.S. from Wayne State University, a M.S. in Mathematics from Youngstown State University and an M.B.A. from Stanford Graduate School of Business. 

Nicki Vasquez, Ph.D.

Chief Portfolio Strategy & Alliance Officer 

Dr. Vasquez has 25 years of biopharmaceutical discovery research and development experience and has lead our alliance and portfolio management since 2015.  Prior to joining Sutro, she was Vice President of Program & Portfolio Management at StemCells, Inc., where she was responsible for establishing project management of research and clinical stage programs exploring HuCNS-SC stem cell therapy for Alzheimer’s Disease, spinal cord injury and dry AMD. Prior to that she was at Elan, where she held positions of increasing responsibility from Alzheimer’s Disease and autoimmune discovery research, to Vice President Research Operations & Program Management, and Vice President Development Program & Portfolio Management. Dr. Vasquez obtained her doctoral degree in immunology from the University of California, San Diego, and received her post-doctoral training at Genentech.

Dr. Nicki Vasquez was recently honored as one of Fierce Pharma 2021 Fiercest Women in Life Sciences. Click the link to read the article,
https://www.fiercepharma.com/special-report/women-life-sciences-2021?oly_enc_id=8908A7445778A3R

 

To view Sutro’s Functional Leadership Team, click here.